JP2015528446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528446A5 JP2015528446A5 JP2015527429A JP2015527429A JP2015528446A5 JP 2015528446 A5 JP2015528446 A5 JP 2015528446A5 JP 2015527429 A JP2015527429 A JP 2015527429A JP 2015527429 A JP2015527429 A JP 2015527429A JP 2015528446 A5 JP2015528446 A5 JP 2015528446A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- instructions
- kit
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/050630 WO2014027996A1 (en) | 2012-08-13 | 2012-08-13 | Improved methods for treating cancer with reduced renal toxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017104084A Division JP2017178960A (ja) | 2017-05-26 | 2017-05-26 | 腎毒性を低減してがんを処置するための改良法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015528446A JP2015528446A (ja) | 2015-09-28 |
| JP2015528446A5 true JP2015528446A5 (OSRAM) | 2015-11-05 |
Family
ID=50101360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527429A Pending JP2015528446A (ja) | 2012-08-13 | 2012-08-13 | 腎毒性を低減してがんを処置するための改良法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150258140A1 (OSRAM) |
| EP (1) | EP2882420A4 (OSRAM) |
| JP (1) | JP2015528446A (OSRAM) |
| CN (1) | CN104736143A (OSRAM) |
| AU (1) | AU2012387681A1 (OSRAM) |
| BR (1) | BR112015003111A2 (OSRAM) |
| CA (1) | CA2882156A1 (OSRAM) |
| EA (1) | EA201590325A1 (OSRAM) |
| IN (1) | IN2015KN00375A (OSRAM) |
| MA (1) | MA37931A1 (OSRAM) |
| SG (1) | SG11201501146VA (OSRAM) |
| WO (1) | WO2014027996A1 (OSRAM) |
| ZA (1) | ZA201501123B (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2654484C1 (ru) * | 2012-05-11 | 2018-05-21 | Ресет Терапьютикс, Инк. | Карбазолсодержащие сульфонамиды в качестве модуляторов криптохрома |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04169531A (ja) * | 1990-11-01 | 1992-06-17 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金錯体を含有するリポソーム製剤 |
| JPH04169532A (ja) * | 1990-11-01 | 1992-06-17 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金錯体含有リポソーム製剤 |
| EP0551169A1 (en) * | 1992-01-10 | 1993-07-14 | Takeda Chemical Industries, Ltd. | Liposome composition and production thereof |
| EP0929293B1 (en) * | 1996-08-23 | 2003-10-22 | Sequus Pharmaceuticals, Inc. | Liposomes containing a cisplatin compound |
| DE19954613A1 (de) * | 1999-11-12 | 2001-05-17 | Enthone Omi Deutschland Gmbh | Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| GR20060100144A (el) * | 2006-03-03 | 2007-10-17 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene | |
| EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| US20120197060A1 (en) * | 2009-06-18 | 2012-08-02 | University Of Utah Research Foundation | Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology |
-
2012
- 2012-08-12 MA MA37931A patent/MA37931A1/fr unknown
- 2012-08-13 US US14/421,392 patent/US20150258140A1/en not_active Abandoned
- 2012-08-13 CN CN201280075225.2A patent/CN104736143A/zh active Pending
- 2012-08-13 EA EA201590325A patent/EA201590325A1/ru unknown
- 2012-08-13 CA CA2882156A patent/CA2882156A1/en not_active Abandoned
- 2012-08-13 AU AU2012387681A patent/AU2012387681A1/en not_active Abandoned
- 2012-08-13 WO PCT/US2012/050630 patent/WO2014027996A1/en not_active Ceased
- 2012-08-13 IN IN375KON2015 patent/IN2015KN00375A/en unknown
- 2012-08-13 BR BR112015003111A patent/BR112015003111A2/pt not_active IP Right Cessation
- 2012-08-13 EP EP12883054.4A patent/EP2882420A4/en not_active Withdrawn
- 2012-08-13 JP JP2015527429A patent/JP2015528446A/ja active Pending
- 2012-08-13 SG SG11201501146VA patent/SG11201501146VA/en unknown
-
2015
- 2015-02-18 ZA ZA2015/01123A patent/ZA201501123B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy | |
| KR102490334B1 (ko) | 암 치료용 아젤니디핀 약학 조성물의 새로운 적응증 | |
| JP2015512398A5 (OSRAM) | ||
| HRP20200636T1 (hr) | Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija | |
| JP2016536352A5 (OSRAM) | ||
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2016528162A5 (OSRAM) | ||
| JP2014512356A5 (OSRAM) | ||
| RU2014119150A (ru) | Модулирование некоторых тирозинкиназ | |
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2014512354A5 (OSRAM) | ||
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| JP2014526456A5 (OSRAM) | ||
| JP2017517520A5 (OSRAM) | ||
| RU2016148887A (ru) | Пиридиновые соединения пладиенолида и способы применения | |
| JP2016519069A5 (OSRAM) | ||
| HRP20201819T1 (hr) | Farmaceutski pripravak za liječenje raka koji sadrži laktatnu metalnu sol | |
| JP2014530181A5 (OSRAM) | ||
| JP2017516827A5 (OSRAM) | ||
| JP2016533373A5 (OSRAM) | ||
| CY1118596T1 (el) | Θεραπευτικος και διαγνωστικος στοχος | |
| JP2013528215A5 (OSRAM) | ||
| JP2019517507A5 (OSRAM) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами |